NCT02944617View on ClinicalTrials.gov

Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 11, 2016

Primary Completion Date

December 19, 2021

Study Completion Date

December 19, 2021

Conditions
DiarrheaMetastatic Renal Cell CarcinomaStage IV Renal Cell Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DIETARY_SUPPLEMENT

Micronutrient-Fortified Probiotic Yogurt

Receive Activia yogurt

DRUG

VEGF-TKI

Must be received as standard of care chemotherapy

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02944617 - Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor | Biotech Hunter | Biotech Hunter